A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Ras proteins, including K-Ras, are GTPases regulating cellular processes at the plasma membrane.
• Mutant K-Ras is a driver in many human cancers, including pancreatic and lung cancers.
• Ferrocene derivatives elevate reactive oxygen species (ROS) and inhibit K-Ras-driven cancers.

Purpose of the Study:

• To investigate a novel ferrocene derivative's effect on K-Ras-driven cancers.
• To elucidate the mechanism of action, focusing on ROS and K-Ras/plasma membrane interactions.
• To determine the role of K-Ras His95 in the observed effects.

Main Methods:

• Testing a novel ferrocene derivative on pancreatic ductal adenocarcinoma and non-small cell lung cancer cell lines.
• Measuring cellular ROS levels and K-Ras plasma membrane binding and signaling.
• Evaluating the effects of antioxidant supplementation.
• Site-directed mutagenesis to investigate the role of K-Ras His95.

Main Results:

• The ferrocene derivative inhibited K-Ras-driven cancer growth by elevating ROS levels.
• The compound abrogated K-Ras plasma membrane binding and signaling in an isoform-specific manner.
• These effects were reversible with antioxidants, and K-Ras His95 oxidation was implicated.

Conclusions:

• The study demonstrates ROS-mediated regulation of K-Ras/plasma membrane binding and signaling via His95 oxidation.
• This provides a mechanism for how oncogenic K-Ras contributes to cancer growth and metastasis.
• The findings suggest therapeutic potential for targeting K-Ras in cancers.